Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD

Respiratory Medicine

Volumn 107, Issue 11, 2013, Pages 1722-1730

  Snell, Noel ^a   Foster, Martyn ^b   Vestbo, Jørgen ^c,d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b Benfleet   (United Kingdom)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

AZD1981; COPD; CRTh2 antagonist

Indexed keywords

AZD 1981; PLACEBO; RECEPTOR BLOCKING AGENT; TERBUTALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; TH2 CELL; TREATMENT DURATION;

AZD1981; COPD; CRTH2 ANTAGONIST;

ACETATES; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDOLES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84887046423     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.06.006     Document Type: Article

References (20)

1. J. Vestbo, S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, A. Anzueto, and P.J. Barnes Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
2. G. Caramori, P. Casolari, G.N. Cavallesco, S. Giuffrè, I. Adcock, and A. Papi Mechanisms involved in lung cancer development in COPD Int J Biochem Cell Biol 43 2011 1030 1044
3. M.D. Eisner, N. Anthonisen, D. Coultas, N. Kuenzli, R. Perez-Padilla, and D. Postma An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease Am J Respir Crit Care Med 182 2010 693 718
4. K. Nagata, H. Hirai, K. Tanaka, K. Ogawa, T. Aso, and K. Sugamura CRTh2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s) FEBS Lett 459 1999 195 199
5. K. Nagata, K. Tanaka, K. Ogawa, K. Kemmotsu, T. Imai, and O. Yoshie Selective expression of a novel surface molecule by human Th2 cells in vivo J Immunol 162 1999 1278 1286
6. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTh2 J Exp Med 193 2001 255 261
7. + Th2 lymphocytes in response to mast cell supernatants Immunology 119 2006 362 368
8. 2 receptor antagonists in development Exp Opin Investig Drugs 19 2010 947 961
9. R. Pettipher, and M. Whittaker Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis J Med Chem 55 2012 2915 2931
10. T. Ulven, and E. Kostenis Novel CRTh2 antagonists: a review of patents from 2006 to 2009 Exp Opin Ther Pat 20 2010 1505 1530
11. D. Singh, P. Cadden, M. Hunter, L.P. Collins, M. Perkins, and R. Pettipher Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Eur Respir J 41 2013 46 52
12. C. Sargent, S. Stinson, J. Schmidt, I. Dougall, R. Bonnert, and S. Paine The effect of a selective CRTh2 antagonist on tobacco smoke (TS) induced airway inflammation and remodelling in the mouse Br J Pharmacol 7 2009 003P
13. K.J. Stebbins, A.R. Broadhead, L.D. Correa, J.M. Scott, Y.P. Truong, and B.A. Stearns Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation Eur J Pharmacol 638 2010 142 149
14. K. Stebbins, J. Evans, and D. Lorrain DP2 receptor antagonists: novel therapeutic target for COPD Mol Cell Pharmacol 2 2010 89 96
15. T. Horiguchi, S. Tachikawa, R. Kondo, M. Shiga, M. Hirose, and K. Fukumoto Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema Arzneim Forsch/Drug Res 52 2002 764 768
16. T. Luker, R. Bonnert, S. Brough, A.R. Cook, M.R. Dickinson, and I. Dougall Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists - discovery of AZD1981 Bioorg Med Chem Lett 21 2011 6288 6292
17. J.A. Schmidt, F.M. Bell, E. Akam, C. Marshall, I.A. Dainty, and A. Heinemann Biochemical and pharmacological characterisation of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma Br J Pharmacol 168 2013 1626 1638
18. AstraZeneca data on file; AZD1981 clinical trials website. Available at: http://www.astrazenecaclinicaltrials.com/therapy-areas/respiratory-inflammation/ %3ffieldValues%5Ball%5D%3d%26fieldValues%5Breportavailable%5D%3d%26fieldValues% 5Brecruitingstatus%5D%3d%26fieldValues%5Bdiseases%5D%3d%26fieldValues%5Bproduct s%5D%3d16000178%26fieldValue%20 [accessed 26.03.13].
19. J.W. Kocks, M.G. Tuinenga, S.M. Uil, J.W. van den Berg, E. Ståhl, and T. van der Molen Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire Respir Res 7 2006 62
20. AstraZeneca data on file; study code: D9831C00002; ClinicalTrials.gov identifier: NCT00766415. Available at: http://www.astrazenecaclinicaltrials.com/ therapy-areas/respiratory-inflammation/?itemId=8595916 [accessed 26.03.13].